Contract Manufacturing in India for Foreign Companies: Partner Selection, Compliance, and Market Entry Strategies

Introduction

For global brands, multinational manufacturers, and international product companies evaluating India as part of China-Plus-One supply chain diversification or as a fresh market entry strategy, contract manufacturing in India has emerged as the most capital-efficient pathway to Indian production capacity in 2026.

The combination of mature contract manufacturing ecosystems in pharmaceuticals, electronics, automotive components, specialty chemicals, food processing, textiles, and consumer goods has positioned India as a leading global manufacturing hub. Additional support comes from the Production Linked Incentive (PLI) framework, with an outlay of INR 1.97 lakh crore and committed investments of approximately INR 2.16 lakh crore by early 2026, alongside cumulative manufacturing FDI exceeding USD 165 billion over the past decade, according to DPIIT.

India's competitiveness is further strengthened by SEBI's BRSR Core value chain disclosure requirements, which are driving audit-grade compliance across supplier networks, and by the country's expanding network of free trade agreements. Key agreements include the India–UAE Comprehensive Economic Partnership Agreement (CEPA), the India–Australia Economic Cooperation and Trade Agreement (ECTA), and the India–EFTA Trade and Economic Partnership Agreement (TEPA). Collectively, these developments make manufacturing partnership in India one of the most attractive global sourcing and production destinations.

Scope of This Guide

This guide answers the foreign sponsor's question directly: how do I set up outsourced manufacturing for foreign companies in India — across partner identification, technical and compliance due diligence, agreement structuring, regulatory navigation, and market entry sequencing. Whether you are entering India for cost-arbitrage manufacturing, market access manufacturing under PLI, China-Plus-One diversification, or building Indian capacity to serve global markets, the framework below applies.

Table of Contents

• Introduction
• Why Contract Manufacturing in India Has Become Strategic for Foreign Companies in 2026
• Engagement Structures - Contract Manufacturing vs Direct Investment
• How to Set Up Contract Manufacturing in India - Six-Phase Framework
• Contract Manufacturing Partner Selection Process India
• Contract Manufacturing Compliance Requirements for Foreign Companies
• Contract Manufacturing Agreement Structure India
• Market Entry Through Contract Manufacturing in India
• Common Mistakes and Best Practices
• Conclusion

1. Why Contract Manufacturing in India Has Become Strategic for Foreign Companies in 2026

Four structural drivers make Indian contract manufacturing strategically consequential for foreign companies in 2026.

1.1 China-Plus-One Routes Manufacturing Capacity to India

Global brands pursuing supply chain diversification under the China-Plus-One framework have routed sustained manufacturing volumes to India since 2020. Cumulative manufacturing FDI exceeding USD 165 billion over the past decade per DPIIT data reflects this structural shift. Manufacturing outsourcing in India is now a default consideration for international brand procurement teams across pharmaceuticals, electronics, automotive components, textiles, specialty chemicals, food processing, and consumer goods. Major brands including Apple, Samsung, Foxconn, Pfizer, Unilever, and others have materially expanded Indian contract manufacturing relationships.

1.2 Capital-Efficient Market Entry

Contract manufacturing enables foreign companies to establish Indian production and market presence without the capital intensity of greenfield facility development. A new pharmaceutical manufacturing facility may require INR 200-1,500 crore investment; an electronics manufacturing plant INR 500-3,000 crore; a specialty chemical facility INR 300-1,500 crore.

Contract manufacturing through qualified Indian partners requires no capital deployment in manufacturing infrastructure - only working capital, qualification, and ongoing management. The capital efficiency makes market entry in India feasible for product companies that lack scale for direct investment.

1.3 PLI Alignment Through Indian Partners

Many PLI schemes (INR 1.97 lakh crore outlay across 14 sectors) require Indian manufacturer participation. Foreign brand sponsors that engage qualified Indian contract manufacturers participating in PLI capture indirect scheme benefits including capacity ramp-up, technology localisation, and cost competitiveness derived from PLI incentives flowing to the manufacturer.

 Sector-specific PLI alignment - particularly in electronics (Large Scale Electronics Manufacturing, IT Hardware, ACC Battery), pharmaceuticals (Bulk Drugs, Medical Devices, Pharmaceuticals), specialty chemicals, and high-efficiency solar PV - provides additional commercial alignment for foreign-brand-Indian-manufacturer partnerships.

1.4 ESG and Audit Cascade Compliance

SEBI BRSR Core requirements with value chain disclosure covering top supply chain partners (accounting for 2 percent of purchases or sales up to 75 percent of value chain activities) increasingly cascade audit obligations to Indian manufacturers. EU CSDDD, UK Modern Slavery Act 2015, US UFLPA, and OECD MNE Guidelines impose parallel due diligence on foreign brand companies sourcing from international suppliers. Foreign companies engaging qualified, audit-mature Indian contract manufacturers reduce regulatory and reputational risk versus engaging unqualified or under-audited suppliers.

2. Engagement Structures - Contract Manufacturing vs Direct Investment

Foreign companies face a strategic choice between contract manufacturing, third-party manufacturing in India through joint ventures, and direct investment via subsidiary or branch establishment. The choice drives capital deployment, risk profile, control depth, and market entry timeline.

Dimension	Contract Manufacturing	Joint Venture	Wholly-Owned Subsidiary
Capital Deployment	Working capital only	Equity contribution to JV	Full capex commitment
Time to Market	6-18 months	12-36 months	24-48 months
Control Level	Quality and IP through agreement	Shared governance	Full operational control
IP Risk	Higher; mitigated by agreement	Moderate; shared with partner	Lowest
Exit Flexibility	Highest; contract-based	Moderate; JV exit complexity	Lowest; full sunk capex
FDI Compliance	Not applicable for goods CM	FDI Policy applies	FDI Policy applies

2.1 The Contract Manufacturing Business Model Pathway

Pure contract manufacturing - where the foreign brand engages an Indian manufacturer to produce branded products under contract without equity participation - suits sponsors prioritising capital efficiency, time to market, and exit flexibility. Common in pharmaceutical CMOs (Contract Manufacturing Organisations), electronics EMS, FMCG private label, and many consumer goods categories. The foreign brand retains IP, brand control, and customer relationships; the Indian manufacturer provides production capability, regulatory licensing, and operational execution.

2.2 The Joint Venture Pathway

Joint ventures suit sponsors requiring deeper strategic alignment, shared market development costs, or local-partner regulatory advantages. JV structures range from minority foreign holdings (under FDI sectoral caps where applicable) through 50:50 partnerships to majority foreign-owned JVs. Press Note 3 of 2020 imposes prior government approval for FDI from entities of countries sharing land borders with India - typically affecting Chinese investment. JV structures require deeper FDI compliance, FEMA 1999 compliance, and structured governance arrangements.

2.3 The Direct Investment Pathway

Direct investment through wholly owned subsidiary establishment under the Companies Act 2013 (with 100 percent FDI permitted under the automatic route in most manufacturing sectors) suits sponsors with material scale commitments and long-term strategic positioning. Foreign investment in manufacturing in India through this route typically applies to sponsors with INR 500+ crore capacity commitments, PLI-anchor positioning, or competitive-IP-sensitive products. The pathway requires longer execution timelines but provides highest level of control and value capture.

2.4 Hybrid Structures

Many foreign companies operate hybrid structures combining contract manufacturing for initial market entry, subsequent JV formation for scale-up, and eventual wholly-owned subsidiary establishment for strategic positions. The progression reduces upfront commitment while building Indian capability and market knowledge. Sequential structuring is particularly common in pharmaceuticals, specialty chemicals, automotive components, and advanced electronics where market dynamics evolve over multi-year horizons.

3. How to Set Up Contract Manufacturing in India - Six-Phase Framework

A step-by-step guide to contract manufacturing in India unfolds across six structured phases. The framework applies across sectors with sector-specific adaptations in pharma, electronics, automotive, chemicals, food, textiles, and consumer goods.

Phase	Activity	Typical Duration
1. Strategy & Market Assessment	Sourcing strategy, target market, sector evaluation	4-8 weeks
2. Partner Identification	Long-list building, screening, capability questionnaire	6-10 weeks
3. Due Diligence	Plant audits, technical, commercial, regulatory, ESG diligence	8-12 weeks
4. Agreement Structuring	Commercial structuring, contract negotiation, IP protection	6-10 weeks
5. Onboarding & Qualification	Customer qualification, pilot production, regulatory transfer	12-24 weeks
6. Commercial Operations	Scale-up, quality monitoring, ongoing governance	Continuous

3.1 Strategy and Market Assessment

The starting decision frames downstream execution. Sourcing objectives - cost arbitrage, India market entry, China-Plus-One diversification, PLI access, or combination. Target market - Indian domestic, India-as-export-platform, or both. Product complexity - regulated (pharma, medical devices), quality-sensitive (electronics, automotive), or standard (FMCG, textiles). Volume profile - small-batch specialty, mid-volume regional, or large-volume export. Time horizon - tactical short-term sourcing or strategic long-term Indian presence.

3.2 Partner Identification Through Established Channels

Partner identification proceeds through industry associations (IDMA, OPPI, Pharmexcil for pharma; ACMA, SIAM for auto; ELCINA, IESA, MAIT for electronics; AIFPA for food; CITI for textiles; EEPC India for engineering), trade shows (CPHI India, Auto Expo, Electronica India, Aahar), Export Promotion Council databases (APEDA, FIEO, EPC sectoral lists), pre-vetted networks of specialist consultancies, and existing brand referrals. The long-list typically narrows from 30-100 potential partners to 8-15 shortlisted candidates through capability questionnaire screening.

3.3 Detailed Due Diligence

Due diligence covers technical capability (equipment, capacity, quality systems, regulatory licences, customer history), commercial structure (financial health, ownership, customer concentration, payment behaviour), regulatory compliance (sector-specific licensing, current audit history, customer audit performance, BIS CRS, sector-specific certifications), ESG and labour compliance (BRSR Core compatibility, ISO 14001/45001 status, labour audit history, modern slavery compliance), and reference verification (3-5 current and former customers). Sector-specific overlays apply - WHO-GMP for pharma; IATF 16949 for automotive; ISO 13485 for medical devices; FSSAI for food.

3.4 Agreement Structuring and Onboarding

Agreement structuring covers commercial terms (pricing model, MOQ, payment, capacity reservation), quality framework (specifications, batch release, audit rights), IP protection (process IP, trademark, design rights, NDA), regulatory cooperation (licensing transfer, customer audit support), and exit provisions. Onboarding includes regulatory product transfer where applicable, customer qualification (typically 6-12 months for major OEM/pharma customers), pilot production, scale-up, and commercial operations launch. End-to-end timeline from strategy through commercial production typically runs 6-18 months.

4. Contract Manufacturing Partner Selection Process India

Structured manufacturing partner selection in India is the single largest determinant of contract manufacturing success. The process unfolds through screening, capability assessment, and reference verification across multiple weighted criteria.

4.1 The Multi-Criteria Selection Framework

Criterion	Weighting	Assessment Approach
Technical capability and capacity	20-25%	Plant audit, equipment review, capacity verification
Regulatory licences and audit history	15-20%	Document review, regulatory database check
Quality systems and certifications	15-20%	ISO/sector-specific audit, batch records
Financial health and stability	10-15%	Audited financials, banking references
ESG and labour compliance	10-15%	ESG audit, BRSR compatibility check
Customer references	10-15%	Reference checks with 3-5 current/former customers
Commercial terms and IP protection	5-10%	Agreement negotiation flexibility
Cultural and operational fit	5-10%	Engagement during plant visits and meetings

4.2 The Plant Audit

Plant audits at shortlisted partners (typically 1-3 days per facility) provide the most consequential information in the selection process. Audit scope: physical facility quality and condition, equipment age and capability, quality system maturity through batch record review, regulatory compliance verification through current licences and recent inspection reports, workforce capability and labour practices, raw material sourcing and traceability, finished goods storage and dispatch, environmental and safety compliance. Multi-dimensional audits (technical plus ESG plus financial) are increasingly standard, often delivered through specialist contract manufacturing due diligence services India to reduce the foreign-brand-internal team burden.

4.3 Reference Checks - The Validation Layer

Reference checks with 3-5 current and former customers per shortlisted partner provide operational reality verification that desktop and audit analysis cannot fully capture. Reference inquiry covers delivery reliability over time, quality consistency, responsiveness to issues, commercial integrity, technical and regulatory cooperation, and the customer's overall experience including any contractual disputes or operational issues. Negative references at the reference stage should generally disqualify partners regardless of strong paper credentials.

4.4 The Pre-Vetted Network Advantage

Foreign companies engaging through pre-vetted specialist networks rather than open-channel discovery typically compress selection timelines by 30-50 percent while improving selection quality. IMARC Engineering operates pre-vetted networks across pharmaceutical CDMOs, electronics EMS, automotive Tier-1/Tier-2 suppliers, specialty chemicals, food processing, cosmetics, textiles, and engineering goods - delivering third-party manufacturing services for global brands India with pre-screened capability, regulatory compliance, financial stability, and ESG maturity.

5. Contract Manufacturing Compliance Requirements for Foreign Companies

The manufacturing compliance in India architecture for foreign-brand contract manufacturing operates across Central statutes, sector-specific regulation, international compliance frameworks, and customer-cascade audit requirements.

5.1 The Indian Statutory Stack

Instrument	Scope	Foreign Company Relevance
Companies Act 2013	Corporate structure of Indian partner / subsidiary	Direct if subsidiary; partner-level otherwise
FEMA 1999 & FDI Policy	Foreign exchange and investment	Direct for capital structures and remittance
FTDR Act 1992	Foreign trade regulation; IEC required	Direct for export/import structures
GST Act 2017	Tax framework with export zero-rating	Direct on commercial flows
OSH Code 2020	Establishment registration (in force 21 Nov 2025)	Partner-level compliance
BIS Act 2016 (CRS)	Compulsory Registration for electronics	Product-level compliance
Drugs and Cosmetics Act 1940	Pharma manufacturing (Schedule M, 1 July 2024)	Pharma product-level
Medical Devices Rules 2017	Medical device manufacturing	Medical device product-level
FSSA 2006	Food manufacturing	Food product-level

5.2 International Compliance Cascade

Foreign companies sourcing from Indian contract manufacturers face parallel obligations from their home jurisdictions. EU Corporate Sustainability Due Diligence Directive (CSDDD) requires large EU-domiciled entities and value chains to conduct human rights and environmental due diligence. EU Corporate Sustainability Reporting Directive (CSRD) requires comprehensive sustainability disclosures including value chain impacts.

UK Modern Slavery Act 2015 requires UK companies to disclose efforts to address modern slavery. US Uyghur Forced Labor Prevention Act (UFLPA) requires US importers to demonstrate goods are not produced using forced labour. OECD Guidelines for Multinational Enterprises and UN Guiding Principles on Business and Human Rights provide international standards. Foreign companies cascade these requirements to Indian partners through audit obligations.

5.3 SEBI BRSR Cascade Through Indian Listed Brand Customers

Where the Indian contract manufacturer also supplies Indian listed brand companies in SEBI BRSR scope, BRSR Core value chain disclosure requirements cascade ESG audit obligations. BRSR Core was introduced through SEBI Circular dated 12 July 2023; subsequent amendments via SEBI Circular dated 28 March 2025. The phased glide path covers Top 150 listed entities from FY 2023-24 expanding through Top 1000 by FY 2026-27. Indian contract manufacturers serving listed Indian customers must maintain audit-grade ESG documentation.

5.4 Sector-Specific Compliance Overlays

Sector-specific compliance differs materially. Pharmaceutical contract manufacturing companies in India requires WHO-GMP for export markets, revised Schedule M (effective 1 July 2024 for large pharma) for domestic, sector-specific licensing under Drugs and Cosmetics Act 1940, and USFDA/EU-EMA inspection readiness for regulated market exports.

Medical devices require ISO 13485 and Medical Devices Rules 2017 compliance. Electronics requires BIS CRS, EMI/EMC testing under TEC, and WPC compliance for wireless devices. Automotive requires IATF 16949, APQP/PPAP, and customer-specific qualifications. Food requires FSSAI licensing at appropriate tier, HACCP, and ISO 22000 alignment.

6. Contract Manufacturing Agreement Structure India

The contract manufacturing agreement is the foundational commercial and legal instrument governing the foreign brand-Indian manufacturer relationship. Comprehensive structuring at contract stage prevents the operational disputes and IP losses that ad-hoc agreements routinely produce.

6.1 Core Commercial Terms

• Pricing model - cost-plus, fixed price per unit, or hybrid; with periodic review provisions
• Minimum order quantities (MOQ) and capacity commitments
• Payment terms - advance, LC, open account; aligned with risk profile
• Delivery terms - Incoterms 2020 for export structures; FOB, CIF, EXW typical
• Forecast and rolling commitment mechanisms supporting capacity planning
• Capacity reservation fees where exclusive capacity is committed
• Termination notice periods and exit transition provisions

6.2 Quality and Technical Framework

• Product specifications with detailed acceptance criteria
• Quality Agreement separate from commercial agreement (typical for regulated sectors)
• Batch release procedures and Certificate of Analysis requirements
• Customer audit rights with defined frequency and scope
• Change control procedures for any process or material modifications
• CAPA tracking for quality findings
• Regulatory document support for foreign-market filings (DMF, ANDA, CMC, etc.)

6.3 Intellectual Property and Confidentiality

• Pre-existing IP ownership clearly preserved
• Process IP - whether developed jointly, by manufacturer, or transferred from brand
• Brand and trademark rights restricted to contracted products
• Confidentiality covering technical specifications, formulations, customer lists
• Non-compete restrictions on manufacturer producing competing products
• Indian Patents Act 1970 and Trade Marks Act 1999 alignment
• Dispute resolution preferably through India-based arbitration (Indian Arbitration and Conciliation Act 1996)

6.4 ESG, Labour, and Audit Obligations

• Compliance with applicable ESG and labour standards
• Audit obligations supporting EU CSDDD, UK Modern Slavery Act, US UFLPA compliance
• BRSR Core data sharing where relevant for Indian-listed-brand customers
• ISO 14001 and ISO 45001 certification commitments where applicable
• Sub-contractor management and disclosure obligations
• Right to remediation for material non-compliance

7. Market Entry Through Contract Manufacturing in India

Foreign companies use Indian contract manufacturing as a structured market entry strategy in India supporting domestic market access, export-from-India operations, or both. The market entry context shapes partner selection, agreement structure, and compliance positioning.

7.1 Domestic Market Entry Through Contract Manufacturing

Foreign brands entering the Indian domestic market through contract manufacturing typically follow a sequenced approach. Initial product testing through pilot batches with Indian partners; brand-building through digital and modern trade channels; supply chain optimisation through contract manufacturer geographic positioning; eventual sales infrastructure development (direct sales force, distributor networks, modern trade partnerships). The contract manufacturing relationship typically scales with market traction - starting from small volumes through pilot phases to material domestic supply as brand presence grows.

7.2 India-as-Export-Platform Strategy

Foreign companies increasingly use Indian contract manufacturing to serve global markets - leveraging India's cost-competitive labour, mature supplier ecosystems, FTA network (UAE CEPA, Australia ECTA, EFTA TEPA, ASEAN agreements), RoDTEP export incentive (INR 18,233 crore FY 2025-26 allocation), and Foreign Trade Policy 2023 framework.

The pattern is particularly common in pharmaceuticals (Indian CDMOs serving regulated markets), electronics (Apple's iPhone manufacturing through Foxconn, Pegatron, Wistron-now-Tata for global supply), textile (Indian production for EU and US brands), and specialty chemicals.

7.3 The Hybrid Market Entry Approach

Many foreign companies execute hybrid strategies - using contract manufacturing initially for both domestic and export markets, eventually establishing direct subsidiary structures once scale economics justify the investment. The progression reduces initial commitment while building Indian operational knowledge. The sequence: Year 1-3 contract manufacturing for market entry and learning; Year 3-7 scaled contract manufacturing with multi-partner structuring; Year 7+ direct subsidiary or JV establishment for strategic positions. Sequential structuring is particularly common in pharmaceuticals, automotive, and consumer goods.

7.4 Regulatory Positioning for Foreign Brands

Foreign brand companies serving the Indian domestic market through contract manufacturing typically require local regulatory positioning - foreign company registration under Companies Act 2013, GST registration for tax compliance, sectoral product registration (e.g., CDSCO for pharma/medical devices, FSSAI for food, BIS CRS for electronics), and trademark registration with Indian Trade Marks Office. India market entry consultants and contract manufacturing advisors typically support this regulatory positioning alongside manufacturing partner engagement - creating a coordinated India operating structure.

8. Common Mistakes and Best Practices

8.1 Selecting Partners on Lowest Quoted Price

Foreign sponsors that select Indian contract manufacturers on lowest quoted price routinely face downstream quality, capacity, or compliance issues that erase any price saving.

Best practice: structured multi-criteria evaluation with price weighting limited to 25-30 percent; total cost of ownership over multi-year horizon; emphasis on quality system maturity, regulatory compliance, and reference verification.

8.2 Inadequate Plant Audit Before Commitment

Engagement based on capability questionnaires and brochures without physical plant audit routinely surfaces gaps post-commitment.

Best practice: mandatory 1-3 day plant audit at every shortlisted partner; sector-specific audit overlays; 3-5 reference checks per shortlisted partner; documented audit findings driving final selection.

8.3 Weak IP Protection in Agreements

Standard supply agreements often inadequately address IP, confidentiality, and non-compete dimensions critical for foreign brands.

Best practice: separate Quality Agreement covering technical dimensions; explicit IP ownership preservation; structured confidentiality with defined enforcement mechanisms; non-compete restrictions appropriate to product category; India-based arbitration provisions.

8.4 Underestimating Regulatory Transfer Complexity

Regulated-product transfers (pharma, medical devices, electronics) involve substantial regulatory documentation, customer audit qualification, and timeline complexity.

Best practice: regulatory pathway mapping at strategy stage; structured product transfer programmes; sector-specific consultant engagement; realistic timeline planning incorporating 6-12 month qualification cycles.

8.5 Treating Compliance as Manufacturer's Responsibility

Foreign brands sometimes assume Indian partners bear full compliance responsibility - missing the brand-level audit obligations under EU CSDDD, UK Modern Slavery Act, US UFLPA, and OECD MNE Guidelines that flow through to the foreign brand.

Best practice: dual-layer compliance approach with brand-level audit programmes alongside manufacturer-level operational compliance; structured ESG audit cycle; transparent supply chain documentation supporting brand disclosure obligations.

Conclusion

Contract manufacturing in India has emerged as the most capital-efficient and time-efficient pathway for foreign companies entering India in 2026. It is anchored in mature contract manufacturing ecosystems across pharmaceuticals, electronics, automotive components, specialty chemicals, food processing, textiles, and consumer goods; the PLI framework; cumulative manufacturing FDI; SEBI's BRSR Core value chain cascade; and the structured Foreign Trade Policy 2023 framework.

China-Plus-One supply chain diversification continues to route material global manufacturing volumes to India, producing both opportunity and complexity for foreign sponsors entering or scaling Indian operations.

Three closing reminders for foreign companies looking for contract manufacturing companies in India. First, invest in structured partner selection through multi-criteria evaluation, plant audits, and reference checks - the upfront investment compresses downstream operational risk by 60-80 percent versus rushed partner selection.

Second, structure agreements comprehensively covering commercial, quality, IP, regulatory, and ESG dimensions through Quality Agreements separate from supply contracts - the agreement quality at contract stage determines dispute frequency and IP protection over multi-year horizons.

Third, plan compliance as a dual-layer system covering brand-level audit obligations (EU CSDDD, UK Modern Slavery Act, US UFLPA, OECD MNE Guidelines) alongside manufacturer-level operational compliance - the brand cannot rely on manufacturer compliance alone to satisfy home-jurisdiction obligations.